These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 332346)

  • 41. Progress report on high-dose methotrexate (NSC-740) with citrovorum rescue in the treatment of metastatic bone tumors.
    Jaffe N
    Cancer Chemother Rep; 1974; 58(2):275-80. PubMed ID: 4598245
    [No Abstract]   [Full Text] [Related]  

  • 42. Prognostic indicators in diffuse large-cell (histiocytic) lymphoma.
    Todd MB; Portlock CS; Farber LR; Holford TR; Bertino JR
    Int J Radiat Oncol Biol Phys; 1986 Apr; 12(4):593-601. PubMed ID: 2422144
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diffuse histiocytic lymphoma. The need for aggressive restaging.
    Weinerman BH; Levitt M; Babick T
    JAMA; 1977 May; 237(22):2403-4. PubMed ID: 323527
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-dose methotrexate-citrovorum factor rescue in the management of brain tumors.
    Djerassi I; Kim JS; Shulman K
    Cancer Treat Rep; 1977 Jul; 61(4):691-4. PubMed ID: 301782
    [No Abstract]   [Full Text] [Related]  

  • 45. Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults.
    Whitecar JP; Bodey GP; Freireich EJ; McCredie KB; Hart JS
    Cancer Chemother Rep; 1972 Aug; 56(4):543-50. PubMed ID: 5081596
    [No Abstract]   [Full Text] [Related]  

  • 46. Long-term survival of patients with localized diffuse histiocytic lymphoma.
    Vokes EE; Ultmann JE; Golomb HM; Gaynor ER; Ferguson DJ; Griem ML; Oleske D
    J Clin Oncol; 1985 Oct; 3(10):1309-17. PubMed ID: 3900300
    [TBL] [Abstract][Full Text] [Related]  

  • 47. "Single"-agent activity of high-dose methotrexate with citrovorum factor rescue.
    Von Hoff DD; Rozencweig M; Louie AC; Bender RA; Muggia FM
    Cancer Treat Rep; 1978 Feb; 62(2):233-5. PubMed ID: 305823
    [No Abstract]   [Full Text] [Related]  

  • 48. Therapy of acute leukemia with the combination of cytosine arabinoside (NSC-63878) and cyclophosphamide (NSC-26271).
    Bodey GP; Rodriguez V; Hart J; Freireich EJ
    Cancer Chemother Rep; 1970 Aug; 54(4):255-62. PubMed ID: 4946010
    [No Abstract]   [Full Text] [Related]  

  • 49. Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma.
    Hollister D; Silver RT; Gordon B; Coleman M
    Cancer; 1982 Nov; 50(9):1690-4. PubMed ID: 6180819
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyclophosphamide (NSC-26271) maintenance therapy after a second remission of childhood acute lymphoblastic leukemia: comparative clinical trial (standard dose versus intermittent high dose versus cyclophosphamide plus cytosine arabinoside (NSC-63878)).
    Albo V; Movassaghi N; Sitarz AL; Hammond D; Weiner J; Reed A
    Cancer Chemother Rep; 1975; 59(6):1097-102. PubMed ID: 769949
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Second-line efficacy of intermediate high-dose methotrexate with citrovorum factor rescue + cyclophosphamide in ovarian cancer.
    Barlow JJ; Piver MS
    Gynecol Oncol; 1979 Apr; 7(2):233-8. PubMed ID: 312234
    [No Abstract]   [Full Text] [Related]  

  • 52. A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer.
    DeConti RC; Schoenfeld D
    Cancer; 1981 Sep; 48(5):1061-72. PubMed ID: 7023649
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The treatment of histiocytic lymphoma.
    Sweet DL; Golomb HM
    Semin Oncol; 1980 Sep; 7(3):302-9. PubMed ID: 6774422
    [No Abstract]   [Full Text] [Related]  

  • 54. Advanced diffuse histiocytic lymphoma, a potentially curable disease.
    DeVita VT; Canellos GP; Chabner B; Schein P; Hubbard SP; Young RC
    Lancet; 1975 Feb; 1(7901):248-50. PubMed ID: 46388
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vincristine effect on methotrexate cerebrospinal fluid concentration.
    Tejada F; Zubrod CG
    Cancer Treat Rep; 1979 Jan; 63(1):143-5. PubMed ID: 311246
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity.
    Nirenberg A; Mosende C; Mehta BM; Gisolfi AL; Rosen G
    Cancer Treat Rep; 1977 Aug; 61(5):779-83. PubMed ID: 302143
    [No Abstract]   [Full Text] [Related]  

  • 57. Combination chemotherapy of non-Hodgkin lymphoma.
    Forcier RJ; McIntyre OR; Nissen NI; Pajak TF; Glidewell O; Holland JF
    Med Pediatr Oncol; 1978; 4(4):351-62. PubMed ID: 364285
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination chemotherapy with cyclophosphamide (NSC-26271), cytosine arabinoside (NSC-63878), and methotrexate (NSC-740) in advanced solid tumors.
    Odujinrin OO; DeConti RC; Bertino JR
    Cancer Chemother Rep; 1975; 59(6):1091-6. PubMed ID: 769948
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High-dose methotrexate for the remission induction of refractory adult acute lymphocytic leukemia.
    Peterson BA; Bloomfield CD
    Med Pediatr Oncol; 1978; 5(1):79-84. PubMed ID: 370537
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Combination chemotherapy with methotrexate, endoxan, and vincristine (M.E.V.) in the treatment of non-Hodgkin's lymphoma (author's transl)].
    Lauria F; Baccarani M; Barbieri E; Fiacchini M; Tura S
    Tumori; 1973; 59(6):401-8. PubMed ID: 4598587
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.